BioNTech's InstaDeep Unit Showcases AI Breakthroughs in Vaccines and Cancer Treatments
BioNTech's InstaDeep Unit Showcases AI Breakthroughs in Vaccines and Cancer Treatments
As part of the event, BioNTech will showcase the Company's approach to AI capability scaling and deployment across BioNTech's pipeline. These updates will cover the introduction of a new near exascale supercomputer, the launch of a novel BFN generative model, and multiple updates on the deployment of AI across BioNTech's immunotherapy pipeline.BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))))), alongside its artificial intelligence ("AI") subsidiary InstaDeep Ltd. ("InstaDeep"), today presents an overview of its AI approach during an edition of the Company's Innovation Series, AI Day.
biontech SE (納斯達克:BNTX, "biontech" 或 "公司"))))), 與其人工智能 ("人工智能") 子公司 InstaDeep Ltd. ("InstaDeep")，今天在公司創新系列活動 AI Day 上概述了其人工智能方法。
"At BioNTech, we are at the forefront of integrating advanced AI to revolutionize individualized medicine. With our in-house AI specialist, InstaDeep, we are pioneering the use of artificial intelligence to develop personalized vaccines and targeted therapies," said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. "By introducing state-of-the-art technologies such as our BFN generative protein model and incorporating AI capabilities across our immunotherapy pipeline, we are unlocking the full potential of AI to deliver innovative vaccines and cancer treatments to patients worldwide".
"在 biontech，我們處於整合先進人工智能以革新個性化醫學的最前沿。憑藉我們的內部人工智能專家 InstaDeep，我們領先運用人工智能開發個性化疫苗和定向療法，"說 Prof. Ugur Sahin萬.D.，biontech CEO 和聯合創始人。"通過引入諸如我們的 BFN 生成蛋白模型等最先進技術，並在免疫療法產品線全面應用人工智能功能，我們正在釋放人工智能的全部潛力，爲全球病人帶來創新疫苗和癌症治療。"
"BioNTech and InstaDeep, as a biotechnology powerhouse with a dedicated AI unit, are uniquely positioned at the intersection of biotechnology and AI," said Karim Beguir, CEO and Co-Founder of InstaDeep, a BioNTech company. "Working closely together and combining expertise from AI research, high performance computing, software and biology is accelerating innovation. A key focus of this collaboration is our DeepChain multiomics design platform. DeepChain is now open for external partnerships, after successful application to several projects, including the mRNA-encoded antibody RiboMab platform. We are excited to harness breakthroughs in both AI and biotechnology synergistically.''
"作爲一家生物技術巨頭的 biontech 和 InstaDeep，擁有專門的人工智能部門，獨特地位於生物技術和人工智能的交匯處，"說 Karim Beguir，InstaDeep CEO 和聯合創始人，biontech 子公司。"密切合作，並結合來自 AI 研究、高性能計算、軟件和生物學的專業知識正加速創新。這種合作的重點是我們的 DeepChain 多組學設計平台。DeepChain 現在已對外開放合作，成功申請參與多個項目，包括 mRNA 編碼抗體 RiboMab 平台。我們很高興能夠協同利用 AI 和生物技術的突破。"
As part of the event, BioNTech will showcase the Company's approach to AI capability scaling and deployment across BioNTech's pipeline. These updates will cover the introduction of a new near exascale supercomputer, the launch of a novel BFN generative model, and multiple updates on the deployment of AI across BioNTech's immunotherapy pipeline.
作爲活動的一部分，biontech 將展示公司在整個產品線上擴展和部署 AI 能力的方法。這些更新將涵蓋新近超級計算機的引入、新型 BFN 生成模型的發佈以及在 biontech 的免疫療法產品線上部署 AI 的多個更新。
The live webcast of the event will be available via this link and will begin at 3:00 pm CEST (2:00 pm BST, 9:00 am EDT). A replay of the webcast will be available shortly after the event's conclusion and archived on BioNTech's website for one year.
活動的現場網絡廣播將通過此鏈接提供，將於 CESt 時間下午 3:00 開始 (英國夏令時下午 2:00, 東部夏令時間上午 9:00)。活動結束後不久將提供網絡廣播的重播，並將存檔在 biontech 的網站上一年。
譯文內容由第三人軟體翻譯。